Improvements in secondary outcomes were consistently greater with combination treatment versus solifenacin 5 mg or 10 mg, but again, treatment differences did not reach statistical significance. 85 The incidence of overall TEAEs was comparable between combination (39% in ≥65 years and 39.7% in ≥75 years age groups) and solifenacin 5 mg (39.4% in ≥65 years and 40.9% in ≥75 years) groups but numerically higher in the solifenacin 10 mg group (48.7% in ≥65 years and 49.1% in ≥75 year age groups).
1
—
—